The agency is investigating the possible side effects in relation to patients who have used medicines containing the active ingredients semaglutide or liraglutide for weight loss. Novo’s latest hit weight-loss drug Wegovy also contains semaglutide.
Novo has burst into the limelight over the last two years after Wegovy and sister diabetes drug Ozempic were found to induce significant weight loss for people, with celebrities and high profile business personalities openly discussing their use of them. The popularity of the medicines has led to supply shortages and delays in launching the drugs in new markets.
Also read: Ozempic was 2023’s buzziest drug
The EMA said it would consider whether its review should be extended to other drugs in the same class, known as GLP-1 receptor agonists.
Novo said in a statement that patient safety is a “top priority” and it takes all reports of adverse events very seriously.
“GLP-1 receptor agonists have been used to treat type 2 diabetes for more than 15 years and for treatment of obesity for eight years, including Novo products such as semaglutide and liraglutide that have been on the market for more than 10 years,” a spokesperson for the company said.